Overview on effectiveness of erenumab, fremanezumab, and galcanezumab in reducing medication overuse headache in chronic migraine patients

Curone, Marcella; Tullo, V.; Didier, H. A.; Bussone, Gennaro

doi:10.1007/s10072-022-06265-8

Cited by 10 publications

(30 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…38 Similarly, CGRP antagonist, CGRP receptor antagonist and CGRP monoclonal antibodies (CGRP-mAbs) have been widely used in the treatment of orofacial migraine and it has been proven that erenumab, fremanezumab, galcanezumab, and others are effective drugs for treating migraine. 69,70 Even, TA B L E 1 Neuropeptides and their agonists or antagonists in orofacial pain. they were approved by the US FDA for the treatment of migraine.…”

Section: Neuropep Tide S and Their Ag Onis Ts Or Antag Onis Ts For Pa...mentioning

confidence: 99%

Role of neuropeptides in orofacial pain: A literature review

Wang,

Liu,

Gou

et al. 2024

J of Oral Rehabilitation

View full text Add to dashboard Cite

BackgroundNeuropeptides play a critical role in regulating pain and inflammation. Despite accumulating evidence has further uncovered the novel functions and mechanisms of different neuropeptides in orofacial pain sensation and transmission, there is deficient systematic description of neuropeptides' pain modulation in the orofacial region, especially in the trigeminal system.ObjectivesThe present review aims to summarise several key neuropeptides and gain a better understanding of their major regulatory roles in orofacial inflammation and pain.MethodsWe review and summarise current studies related to calcitonin gene‐related peptide (CGRP), substance P (SP), opioid peptide (OP), galanin (GAL) and other neuropeptides' functions and mechanisms as well as promising targets for orofacial pain control.ResultsA number of neuropeptides are clearly expressed in the trigeminal sensory system and have critical functions in the transduction and pathogenesis of orofacial pain. The functions, possible cellular and molecular mechanisms have been introduced and discussed. Neuropeptides and their agonists or antagonists which are widely studied to be potential treatment options of orofacial pain has been evaluated.ConclusionsVarious neuropeptides play important but distinct (pro‐nociceptive or analgesic) roles in orofacial pain with different mechanisms. In summary, CGRP, SP, NPY, NKA, HK‐1, VIP mainly play proinflammatory and pro‐nociceptive effects while OP, GAL, OXT, OrxA mainly have inhibitory effects on orofacial pain.

show abstract

Section: Neuropep Tide S and Their Ag Onis Ts Or Antag Onis Ts For Pa...mentioning

confidence: 99%

Role of neuropeptides in orofacial pain: A literature review

Wang,

Liu,

Gou

et al. 2024

J of Oral Rehabilitation

View full text Add to dashboard Cite

show abstract

“…Erenumab (CM) [66] Fremanezumab (CM) [67] Galcanezumab (CM) [68] Eptinezumab Summary of AEs (safety analysis set).…”

Section: Migraine Patients With Comorbid Depression And/or Anxietymentioning

confidence: 99%

“…[62,64] Real-world studies have confirmed the efficacy of erenumab for the preventive treatment of CM in patients with MOH. [65][66][67][68] In a prospective multicenter study of 396 patients with CM and MOH receiving erenumab, a ≥50% reduction in monthly headache days (MHD) was achieved by 51% of participants and a ≥75% reduction in MHD was achieved by 20% of participants at 3 months following initiation of treatment. [65] Erenumab therapy was also associated with significant decreases in mean monthly pain medication intake, disability (assessed using the 6-item Headache Impact Test), and mean pain intensity.…”

Section: Erenumabmentioning

confidence: 99%

“…[71,72,77] Further, there is now limited evidence from real-world studies in patients with AMO, MOH, and psychiatric comorbidities that support the findings of these subgroup analyses, demonstrating the effectiveness of CGRP pathway-targeted mAbs for preventive treatment of migraine in these populations. [65][66][67][68]73,74] In the current review, we have restricted our discussion of treatment options for migraine complicated by AMO or the presence of psychiatric comorbidities to CGRP pathway-targeted mAbs, as the first disease-specific treatment options developed for the preventive treatment of migraine. Although additional small molecule CGRP pathway-targeted preventive treatments, atogepant and rimegepant, have been approved for the preventive treatment of migraine, [89,90] there is currently a lack of published evidence for the efficacy of these treatments for patients with migraine with AMO or psychiatric comorbidities.…”

Section: Safety and Tolerability Of Cgrp-pathway Targeting Mabsmentioning

confidence: 99%

Section: Treatment Of Migraine With Amo or Psychiatric Comorbidities:...mentioning

confidence: 99%

See 2 more Smart Citations

Burden of migraine with acute medication overuse or psychiatric comorbidities and treatment with CGRP pathway-targeted monoclonal antibodies: A review

et al. 2023

View full text Add to dashboard Cite

Migraine is a complex and often debilitating neurological disease that affects more than 1 billion people worldwide. It is characterized by moderate-to-intense, throbbing headache attacks that are worsened by activity and is associated with nausea, vomiting, and sensitivity to light and sound. Migraine, ranked the second leading cause of years lived with disability by the World Health Organization, can diminish patients’ quality of life and bring significant personal and economic burden. Furthermore, migraine patients with a history of acute medication overuse (AMO) or psychiatric comorbidities, such as depression or anxiety, may experience even greater impairment and burden, and their migraine may be more difficult-to-treat. Appropriate treatment of migraine is essential to reduce this burden and improve patient outcomes, especially for those with AMO or psychiatric comorbidities. There are several available preventive treatment options for migraine, though many of these are not migraine-specific and may have limited efficacy and/or poor tolerability. The calcitonin gene-related peptide pathway plays a key role in the pathophysiology of migraine, and monoclonal antibodies that target the calcitonin gene-related peptide pathway have been developed as specific preventive treatments for migraine. Four of these monoclonal antibodies have been approved for the preventive treatment of migraine after demonstrating favorable safety and efficacy profiles. These treatments offer substantial benefits for migraine patients, including those with AMO or common psychiatric comorbidities, by reducing monthly headache days and migraine days, days of acute medication use, and disability measures, as well as improving quality of life.

show abstract